In this study, tissue EGFR results would have yielded additional findings in 5.56% (3/54) of cases, for which plasma NGS did not find the EGFR mutation present in the tumor, supporting the complementary plasma testing would be the most informative approach for the NSCLC patient population. This evidence concerns the gene EGFR and non-small cell lung carcinoma.